Search
Research
Prevalence of respiratory viruses in community-acquired pneumonia in children: a systematic review and meta-analysisRespiratory viruses are increasingly detected in children with community-acquired pneumonia but prevalence estimates vary substantially. We aimed to systematically review and pool estimates for 22 viruses commonly associated with community-acquired pneumonia.
News & Events
Perth mums play instrumental part in world-first vaccineNew mothers in Perth are teaming up with researchers at The Kids Research Institute Australia in a global bid to develop the first vaccine to prevent Respiratory Syncytial Virus (RSV) disease.
Research
Response after one dose of monovalent influenza A (H1n1) 2009 vaccine in infants and children - preliminary reportTo assess the immunogenicity and safety of a 2009 influenza A(H1N1) vaccine in children.
Research
HPV prevalence in Canberra high school students: significance for vaccination strategies and adolescent healthHPV prevalence in Canberra high school students: significance for vaccination strategies and adolescent health.
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Research
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescentsThis trial evaluated the lot consistency, early immune responses and safety of the vaccine against serogroup B Neisseria meningitidis (4CMenB) - in 11 to 17...
Research
Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.This study was designed to compare data collected via SMS and telephone for the purposes of monitoring vaccine safety.
Research
A randomized phase I study of the safety and immunogenicityIn this study of healthy adults aged 50-85 and 18-24 years, SA3Ag elicited a rapid and robust immune response and was well tolerated, with no notable safety...
Research
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccinationIn Australia, following the introduction of serogroup C meningococcal (MenC) conjugate vaccine for toddlers and catch-up immunization through adolescence,...